Responsiveness to reduced dosage of rituximab in Chinese patients with neuromyelitis optica
- 20 August 2013
- journal article
- case report
- Published by Wolters Kluwer Health in Neurology
- Vol. 81 (8), 710-713
- https://doi.org/10.1212/wnl.0b013e3182a1aac7
Abstract
Objective: To determine the effect of a lower dose of rituximab in depleting B lymphocytes, maintaining low B-cell counts, and relapse in patients with neuromyelitis optica (NMO) and NMO spectrum disorders. Methods: We treated 5 Chinese patients with deteriorating NMO and NMO spectrum disorders with a 100-mg IV infusion of rituximab once a week for 3 consecutive weeks, followed by additional infusion of the same dosage depending on circulating B-cell repopulation. Results: This reduced dosage of rituximab was sufficient to deplete B cells and maintain low B-cell counts. None of the treated patients experienced relapse, and all patients exhibited stabilized or improved neurologic function during the 1-year follow-up period. MRI revealed the absence of new lesions, no enhancement in spinal cord and brain, a significant shrinkage of spinal cord segments, and a reduction/disappearance of previous brain lesions. Conclusion: A lower dosage of rituximab may be sufficient in depleting B cells, maintaining low B-cell counts, and preventing disease progression in Chinese patients with NMO.Keywords
This publication has 10 references indexed in Scilit:
- Aquaporin 4 and neuromyelitis opticaThe Lancet Neurology, 2012
- Rituximab dosing and monitoring strategies in neuromyelitis optica patients: creating strategies for therapeutic successMultiple Sclerosis Journal, 2012
- Repeated Treatment With Rituximab Based on the Assessment of Peripheral Circulating Memory B Cells in Patients With Relapsing Neuromyelitis Optica Over 2 YearsArchives of Neurology, 2011
- Impact of rituximab on relapse rate and disability in neuromyelitis opticaMultiple Sclerosis Journal, 2011
- Use and monitoring of low dose rituximab in myasthenia gravisJournal of Neurology, Neurosurgery & Psychiatry, 2010
- Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesisThe Lancet Neurology, 2010
- Treatment of Neuromyelitis Optica With RituximabArchives of Neurology, 2008
- Activity and safety profile of low-dose rituximab for the treatment of autoimmune cytopenias in adultsHaematologica, 2007
- Diagnosis and Treatment of Neuromyelitis OpticaThe Neurologist, 2007
- An open label study of the effects of rituximab in neuromyelitis opticaNeurology, 2005